At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
MGTA-456drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
In Brief
A Phase 2 clinical trial evaluating MGTA-456 for Inherited Metabolic Disorders (IMD). Completed, enrolled 8 participants across 2 sites.
Detailed Summary
This study is designed to assess the safety and efficacy of using MGTA-456 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInherited Metabolic Disorders (IMD)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartFeb 2018
Primary CompletionFeb 2020
Study CompletionJan 2021
TodayJul 2026
First PostedJan 23, 2018
Enrollment StartFeb 9, 2018
Primary CompletionFeb 10, 2020
Study CompletionJan 15, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.4 years ago
Interventions
MGTA-456drug
Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.